Biologics in China: A 3-legged Race between Innovation, Biosimilars

At the recent ChinaBio® Partnership Forum, a Plenary Panel discussion of innovative biologics, with CEOs of four China biotechs participating, inevitably brought up biosimilars. The panel members concluded it is difficult to develop innovative molecules without also producing biosimilars, because China biotechs need to adopt a twin strategy to survive. Nevertheless, innovative biotech drugs, developed in China, will become a major factor in China's market. BioWorld, the ThomsonReuters newsletter, summarized the panel discussion and allowed us to reprint their article. More details.... Share this with colleagues: // //